Poseida Therapeutics — Company Overview, News & Financial Data
Poseida Therapeutics is a biotech firm advancing CAR-T therapies and gene editing for cancer and rare diseases.
About Poseida Therapeutics
Poseida Therapeutics (NASDAQ:PSTX) is a biotechnology company focused on the development of innovative cell and gene therapies. Utilizing groundbreaking technology, Poseida seeks to engineer life-saving treatments for patients with cancer and rare diseases. The company's diverse pipeline includes unique approaches to CAR-T therapies for solid tumors and hematological malignancies, alongside cutting-edge gene editing technologies aimed at genetic disorders. With a commitment to advancing medicine and improving lives, Poseida Therapeutics is dedicated to pushing the boundaries of science to deliver new therapies that can address unmet medical needs.
Snapshot
Operations
Produtos e/ou serviços de Poseida Therapeutics
- Novel gene therapies leveraging non-viral delivery platforms aimed at treating severe genetic diseases, focusing on high precision and safety.
- CAR-T programs targeting solid tumors and hematological malignancies, utilizing unique technology for enhanced cancer cell targeting.
- In-house T-cell engineering platform to develop off-the-shelf CAR-T therapies, reducing treatment time and cost for patients.
- Gene editing tools based on proprietary DNA-cutting enzymes, offering potential for correction of a wide array of genetic disorders.
- Liver-directed therapies using non-viral gene delivery techniques for treating metabolic diseases, focusing on improving efficacy and reducing adverse effects.
- Partnerships with major pharmaceutical companies to accelerate the development and commercialization of advanced therapies in areas of unmet medical need.
equipe executiva do Poseida Therapeutics
- Mr. Mark J. Gergen J.D.Executive Chairman of the Board
- Ms. Johanna M. Mylet CPAChief Financial Officer
- Mr. Loren WagnerChief Operations Officer
- Ms. Kristin MartinChief People & Administration Officer
- Mr. Alexander ChapmanSenior VP of Investor Relations & Corporate Communications
- Mr. Harry J. Leonhardt Esq., J.D.General Counsel, Chief Compliance Officer & Corporate Secretary
- Dr. Devon J. Shedlock Ph.D.Chief Scientific Officer of Cell Therapy
- Ms. Lisa PortaleSenior Vice President of Regulatory Affairs
- Dr. Jeffrey W. Winkelman J.D., Ph.D.Senior VP & Chief Patent Counsel
- Ms. Karen Basbaum M.B.A.Senior Vice President of Business Development